5-ALA Publications

image

Published a research paper on the safety and usefulness of ALA in the journal of Diabetes Research in a food intervention study in Bahrain’s type 2 diabetic patients

26 September 2016
SBI Holdings Co., Ltd. SBI Pharma Co., Ltd. SBI Pharma Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative Director), a subsidiary of ...Read More
image

The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain

23 August 2016
Feryal Al-Saber,1 Waleed Aldosari,1 Mariam Alselaiti,1 Hesham Khalfan,1 Ahmed Kaladari,1 Ghulam Khan,2 George Harb,3 Riyadh Rehani,2 Sizuka Kudo,4 Aya Koda,4 Tohru Tanaka,4 Motowo Nakajima4 et al. This study in patients with type ...Read More
image

5-Aminolevulinic acid regulates the inflammatory response and all immune reaction

28 November 2015
Author links open overlay panel MasayukiFujinoab, YoshiakiNishioa, HidenoriItoc, TohruTanakac, Xiao-KangLia A Division of Transplantation Immunology, National Research Institute for Child ...Read More
image

Safety test of a supplement, 5-aminolevulinic acid phosphate with sodium ferrous citrate, in diabetic patients treated with oral hypoglycemic agents

30 September 2014
Safety test of a supplement, 5-aminolevulinic acid phosphate with sodium ferrous citrate, in diabetic patients treated with oral hypoglycemic agents ...Read More
image

Synergy of ferrous ion on 5-aminolevulinic acid-mediated growth inhibition of Plasmodium falciparum

24 October 2013
Keisuke Komatsuya, Masayuki Hata, Emmanuel O. Balogun, Kenji Hikosaka, Shigeo Suzuki, Kiwamu Takahashi, Tohru Tanaka, Motowo Nakajima, Shun-Ichiro Ogura, Shigeharu Sato, Kiyoshi Kita Abstract Haem biosynthesis appeared to be a ...Read More
image

5-aminolevulinic acid, a precursor of heme, reduces both fasting and postprandial glucose levels in mildly hyperglycemic subjects

15 July 2013
5-aminolevulinic acid, a precursor of heme, reduces both fasting and postprandial glucose levels in mildly hyperglycemic subjects Project Research Center ...Read More

News Page – Disclaimer

The purpose of this page is to provide you an overview of the business in the industry & market information. Information in this page are derived from internal estimates, studies, researches conducted by third parties and general publications, as well as from sources that are considered reliable, by ABBACI Health (hereinafter referred to as “producers”). Industry publications, studies, and surveys usually indicate the data used are originated from sources that are considered reliable, but no guarantee upon the accuracy or completeness of such data. Producers believe these studies and publications are safe, but they have not independently verified the market and industry data from third-party sources. Similarly, producers think that their internal researches and information about the company is reliable, but not independently validated. Therefore, the content of this prospectus and its accuracy, including the realization or reasonableness of any forecasts, management estimates, prospects or returns, are not expressed or guaranteed by the producers.

The producer is not responsible for providing updates, corrections or other new data for any of the prospectus. This page contains forecasts, as well as potential future events, possible outcomes and projected growth (collectively referred to as “forward-looking statements” or “forward-looking projections”). Producers and their employees are not responsible for relying on or using the data of
this page, or/and any liability of any nature to further convey the relevant data in writing or verbally. As this page is a confidential document, the content is strictly regulated and, without the express consent of the company or the producer, all or part of the data of this page may not be used, reproduced, transmitted, altered, published, stored, duplicated or otherwise used for any purpose.

This document is for informational purposes only and does not constitute an offer, advertisement or invitation to the public.